ANDREW TIMPSON
@Silverarc Capital Management, Llc
Latest period2024 - Q3ReportedManaged Assets$445.291MTotal holdings69
Assets growth rate5.06%Assets growth rate (2-Q avg)11.39%Continuous growth in asset value6 quarters
Portfolio positions
This chart displays the top 10 holdings in Silverarc Capital Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 69 positions.
Assets under management
The assets under management (AUM) of Silverarc Capital Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 6 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 445.291M in assets, with a quarterly growth rate of 5.06% and a 2-quarter average growth rate of 11.39%. The portfolio is managed by ANDREW TIMPSON, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CNTACentessa Pharmaceuticals Plc
| 2.68% | $11.906M 744,592 shares@ $15.99 avg price | New Position |
URGNUrogen Pharma Ltd
| 2.58% | $11.444M 901,129 shares@ $12.7 avg price | Decreased -18.22% |
ORICOric Pharmaceuticals Inc
| 2.54% | $11.27M 1.099M shares@ $10.26 avg price | Increased 2.21% |
PSTXPoseida Therapeutics Inc
| 2.37% | $10.546M 3.688M shares@ $2.86 avg price | Increased 2.21% |
VRNAVerona Pharma Plc
| 2.26% | $10.037M 348,866 shares@ $28.78 avg price | Increased 14.53% |
ALNYAlnylam Pharmaceuticals Inc
| 2.21% | $9.839M 35,774 shares@ $275.03 avg price | Decreased -0.62% |
GERNGeron Corp
| 1.84% | $8.179M 1.802M shares@ $4.55 avg price | Increased 80.29% |
CCCCC4 Therapeutics Inc
| 1.67% | $7.398M 1.298M shares@ $5.71 avg price | Decreased -10.04% |
SNDXSyndax Pharmaceuticals Inc
| 1.64% | $7.291M 378,746 shares@ $19.26 avg price | Increased 2.37% |
PCVXVaxcyte Inc
| 1.56% | $6.913M 60,500 shares@ $114.27 avg price | Increased 2320% |